Skip to Content

Dolasetron Disease Interactions

There is 1 disease interaction with dolasetron:


Dolasetron (applies to dolasetron) QT interval prolongation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Abnormal Electrocardiogram, Arrhythmias, Congestive Heart Failure, Electrolyte Abnormalities, Hypokalemia, Ischemic Heart Disease, Magnesium Imbalance

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.


  1. "Product Information. Anzemet (dolasetron)." Hoechst Marion-Roussel Inc, Kansas City, MO.

Dolasetron drug interactions

There are 341 drug interactions with dolasetron

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.